Since FLCs are byproducts of antibody production, circulating FLCs have been postulated to act as a biomarker of chronic inflammation in patients with type 2 diabetes (Matsumori et al., 2020), and a potential surrogate measure of insulin sensitivity. This evidence concerns the gene INS and type 2 diabetes mellitus.